These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 15812265)

  • 21. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.
    Yoshimura R; Umene-Nakano W; Suzuki A; Ueda N; Miyamoto K; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    Hum Psychopharmacol; 2009 Aug; 24(6):489-94. PubMed ID: 19606452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment.
    Takahashi H; Yoshida K; Ito K; Sato K; Kamata M; Higuchi H; Shimizu T; Ito K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K
    Eur Neuropsychopharmacol; 2002 Oct; 12(5):477-81. PubMed ID: 12208565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
    Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
    JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
    Kiev A; Feiger A
    J Clin Psychiatry; 1997 Apr; 58(4):146-52. PubMed ID: 9164424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment.
    Putzhammer A; Schoeler A; Rohrmeier T; Sand P; Hajak G; Eichhammer P
    Psychopharmacology (Berl); 2005 Mar; 178(2-3):303-8. PubMed ID: 15322730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
    J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics.
    Javors MA; Seneviratne C; Roache JD; Ait-Daoud N; Bergeson SE; Walss-Bass MC; Akhtar FZ; Johnson BA
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):7-13. PubMed ID: 15610939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.
    Zanardi R; Serretti A; Rossini D; Franchini L; Cusin C; Lattuada E; Dotoli D; Smeraldi E
    Biol Psychiatry; 2001 Sep; 50(5):323-30. PubMed ID: 11543734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene.
    Perna G; Favaron E; Di Bella D; Bussi R; Bellodi L
    Neuropsychopharmacology; 2005 Dec; 30(12):2230-5. PubMed ID: 16034444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.
    Yoshida K; Ito K; Sato K; Takahashi H; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):383-6. PubMed ID: 11817517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin transporter polymorphism and bleeding time during SSRI therapy.
    Hougardy DM; Egberts TC; van der Graaf F; Brenninkmeijer VJ; Derijks LJ
    Br J Clin Pharmacol; 2008 May; 65(5):761-6. PubMed ID: 18279474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotonin syndrome caused by minimum doses of SSRIS in a patient with spinal cord injury.
    Satoh K; Takano S; Onogi T; Ohtsuki K; Kobayashi T
    Fukushima J Med Sci; 2006 Jun; 52(1):29-33. PubMed ID: 16995352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse.
    Weizman A; Weizman R
    Pharmacogenomics; 2000 Aug; 1(3):335-41. PubMed ID: 11256582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine.
    Iga J; Ueno S; Yamauchi K; Motoki I; Tayoshi S; Ohta K; Song H; Morita K; Rokutan K; Ohmori T
    Neurosci Lett; 2005 Nov; 389(1):12-6. PubMed ID: 16055263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
    Rapaport M; Coccaro E; Sheline Y; Perse T; Holland P; Fabre L; Bradford D
    J Clin Psychopharmacol; 1996 Oct; 16(5):373-8. PubMed ID: 8889909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.